Melatonin for sleep disorders in children with neurodevelopmental disorders: protocol for a systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
29 11 2022
Historique:
entrez: 29 11 2022
pubmed: 30 11 2022
medline: 2 12 2022
Statut: epublish

Résumé

Neurodevelopmental disorders are a group of disorders thought to be associated with the functioning of the brain and the nervous system. Children with neurodevelopmental disorders often have sleep-related comorbidities that may negatively affect quality of life for both the children and their families. Melatonin is one of the most used interventions in children with neurodevelopmental disorders and sleep disorders. Previous reviews have investigated the effects of melatonin for sleep disorders in children with neurodevelopmental disorders, but these had important limitations, such as inadequate analysis of adverse effects, small sample sizes and short follow-up. This is a protocol for a systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials. The protocol is reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols. We will search for published and unpublished trials in the Cochrane Central Register of Controlled Trials, MEDLINE Ovid, Embase Ovid, LILACS, Science Citation Index Expanded, Conference Proceedings Citation Index-Science, PsycINFO, ClinicalTrials.gov and the International Clinical Trials Registry Platform. We will search the databases from their inception without language restrictions. We will also request clinical study reports from regulatory authorities and pharmaceutical companies. Review authors working in pairs will screen reports, extract data and conduct risk of bias assessments using the Cochrane Risk of Bias tool. We will include randomised clinical trials comparing melatonin versus placebo or no intervention for sleep disorders in children with neurodevelopmental disorders. Primary outcomes will be total sleep time and adverse effects. Secondary outcomes will be quality of life of the child and caregivers and sleep onset latency. Data will be analysed using random-effects and fixed-effect meta-analyses. Certainty of evidence will be assessed with Grading of Recommendations, Assessment, Development and Evaluation approach. Ethical approval was not required for this protocol. The systematic review will be published in a peer-reviewed journal. CRD42022337530.

Identifiants

pubmed: 36446459
pii: bmjopen-2022-065520
doi: 10.1136/bmjopen-2022-065520
pmc: PMC9710329
doi:

Substances chimiques

Melatonin JL5DK93RCL

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e065520

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMC Med Res Methodol. 2010 Oct 01;10:90
pubmed: 20920306
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
J Paediatr Child Health. 2015 Jun;51(6):584-9
pubmed: 25643981
BMC Med Res Methodol. 2017 Dec 6;17(1):162
pubmed: 29207961
Dev Med Child Neurol. 2011 Sep;53(9):783-792
pubmed: 21518346
Eur J Med Chem. 2020 Jan 1;185:111847
pubmed: 31727472
Dialogues Clin Neurosci. 2003 Dec;5(4):343-52
pubmed: 22033558
BMJ. 2012 Nov 05;345:e6664
pubmed: 23129488
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Bioessays. 2014 Aug;36(8):778-87
pubmed: 24903552
Child Adolesc Psychiatry Ment Health. 2020 Mar 10;14:10
pubmed: 32175006
J Clin Epidemiol. 2008 Jan;61(1):64-75
pubmed: 18083463
Brain Sci. 2020 Apr 07;10(4):
pubmed: 32272607
PLoS One. 2013 May 17;8(5):e63773
pubmed: 23691095
Stat Med. 1987 Apr-May;6(3):341-50
pubmed: 3616287
BMJ Open. 2016 Aug 12;6(8):e011890
pubmed: 27519923
Sleep Med Clin. 2015 Jun;10(2):181-7
pubmed: 26055866
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Endocr Rev. 2018 Dec 1;39(6):990-1028
pubmed: 30215696
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Transl Med. 2019 Mar 12;17(1):77
pubmed: 30871585
Stat Med. 2006 Oct 30;25(20):3443-57
pubmed: 16345038
J Am Acad Child Adolesc Psychiatry. 2017 Nov;56(11):948-957.e4
pubmed: 29096777
Dev Med Child Neurol. 2019 Aug;61(8):880-890
pubmed: 30710339
Sleep Med. 2010 Aug;11(7):692-700
pubmed: 20621556
Res Dev Disabil. 2011 May-Jun;32(3):939-62
pubmed: 21296553
BMC Med Res Methodol. 2014 Nov 21;14:120
pubmed: 25416419
J Am Acad Child Adolesc Psychiatry. 2021 Feb;60(2):252-261.e3
pubmed: 31982581
Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):11
pubmed: 18507848
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Can Fam Physician. 2016 Apr;62(4):315-7
pubmed: 27076541
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Curr Psychiatry Rep. 2016 Jan;18(1):6
pubmed: 26719309
Dialogues Clin Neurosci. 2020 Mar;22(1):65-72
pubmed: 32699506
BMC Med Res Methodol. 2014 Feb 18;14:25
pubmed: 24548571
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Int J Epidemiol. 2009 Feb;38(1):276-86
pubmed: 18824467
BMJ Open. 2015 Jan 28;5(1):e006233
pubmed: 25631309
J Clin Epidemiol. 2008 Aug;61(8):763-9
pubmed: 18411040
Nat Sci Sleep. 2019 Jan 31;11:1-10
pubmed: 30774488
Eur Child Adolesc Psychiatry. 2021 Sep;30(9):1339-1350
pubmed: 32699990
Arch Dis Child. 2018 Dec;103(12):1155-1162
pubmed: 29720494
J Pediatr Neurosci. 2015 Oct-Dec;10(4):304-7
pubmed: 26962332
Exp Gerontol. 2004 Nov-Dec;39(11-12):1723-9
pubmed: 15582288
Sleep. 2005 Oct;28(10):1271-8
pubmed: 16295212
Int J Epidemiol. 2009 Feb;38(1):287-98
pubmed: 18824466
Sleep Med Rev. 2005 Feb;9(1):25-39
pubmed: 15649736
Neurol Res. 2017 Jun;39(6):559-565
pubmed: 28460563
Biol Psychiatry. 2005 Jan 15;57(2):134-8
pubmed: 15652871
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Caroline Kamp Jørgensen (CK)

Copenhagen Trial Unit, Centre for Clinical Intervention Research, Capital Region of Denmark, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark caroline.joergensen@ctu.dk.
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Rikke Hermann (R)

Copenhagen Trial Unit, Centre for Clinical Intervention Research, Capital Region of Denmark, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Centre for Children, Youth, and Families, Glostrup, Denmark.

Sophie Juul (S)

Copenhagen Trial Unit, Centre for Clinical Intervention Research, Capital Region of Denmark, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Pascal Faltermeier (P)

Copenhagen Trial Unit, Centre for Clinical Intervention Research, Capital Region of Denmark, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
MSH Medical School Hamburg, University of Applied Sciences and Medical University, Hamburg, Germany.

Mark Horowitz (M)

Research and Development Department, North East London NHS Foundation Trust (NELFT), London, UK.

Joanna Moncrieff (J)

Research and Development Department, North East London NHS Foundation Trust (NELFT), London, UK.
Division of Psychiatry, University College London, London, UK.

Christian Gluud (C)

Copenhagen Trial Unit, Centre for Clinical Intervention Research, Capital Region of Denmark, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Janus Christian Jakobsen (JC)

Copenhagen Trial Unit, Centre for Clinical Intervention Research, Capital Region of Denmark, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH